Generare raises €20M with molecular data no AI model in the world has ever seen
In 2025 alone, Generare characterized five times more novel molecules than every other player in the field combined
Advertisement
Generare – the techbio startup generating novel, high-quality molecular data for drug development by decoding what life wrote – has raised €20M in Series A funding co-led by Alven and Daphni with participation from all existing investors, including Galion.exe, Teampact Ventures and VIVES Partners. The funding will be used to increase Generare's drug discovery compound library, grow its world-class team and scale its proven discovery platform to meet growing demand from pharmaceutical giants and agrochemical companies.
Decoding what life wrote
Founded in 2023 by CEO Guillaume Vandenesch and CSO Dr Vincent Libis, Generare is building the highest quality dataset of untapped molecular chemistry: a growing library of novel compounds characterized for structure, biological activity and drug potential.
Drug discovery has operated inside the same narrow chemical space for decades, not by choice but because the data outside it didn't exist. Encoded in microbial genomes is a reservoir of molecular chemistry that evolution has spent three billion years writing – approximately 97% of which remains unread. Generare is generating that missing data, at a quality and scale the field has never seen, making it genuinely usable for drug development.
Generare's proprietary high-throughput cloning and sequencing technology, validated through ERC-funded academic research and multiple peer-reviewed publications, decodes this cryptic chemistry at scale. It screens tens of thousands of microbial genomes, identifies gene sequences most likely to produce bioactive molecules, expresses them, and characterizes the resulting compounds for structure, biological activity and drug potential.
Generare specialises in small molecules – the class of compounds behind the world’s best-known medicines – and each new small molecule it uncovers becomes a new data point, feeding a dataset that grows with every cycle.
Guillaume Vandenesch, CEO and co-founder, Generare said: ”Drug discovery has a data problem. The entire field trains its models on the same recycled chemistry and expects different outcomes. The bottleneck is not algorithms, it is the absence of genuinely novel, high-quality molecular data and we’re solving that by building the largest proprietary dataset
of cryptic small molecules. These molecules, shaped by 3 billion years of evolution and with drug properties no synthetic library can match, will fuel the next century of drug discovery.”
Molecular data no AI model has ever been trained on
This compounding cycle is what makes Generare's dataset so valuable to partners, including some of the world's most recognizable pharmaceutical companies, and is increasingly critical as AI reshapes drug discovery. AI can accelerate the search for new medicines, but it can’t create truly novel chemistry to learn on. Without novel data, models will keep converging on the same outcomes, regardless of their sophistication. Feed them genuinely new structures selected by evolution with the corresponding biological activity, and the impact multiplies.
Market-leading traction
In just three years, Generare has become the prominent platform generating more evolution-based molecular data than anyone else. In 2025, all players combined discovered a few dozen new molecules; Generare alone revealed over 200. These molecules are now being used by research laboratories to develop new medicines for life threatening diseases.
The funding will enable Generare to scale this capacity 10-fold by 2027 to 2,000+ molecules, with a view of growing past 10,000 over time and effectively compressing what took a century of discovery into a matter of years. It will enable the near-doubling of Generare's 25-strong team of computational biologists, chemists, synthetic biologists, technicians and engineers, drawn from France, the UK, the US, Germany, Australia and beyond. Among those advising the company are Dr Frank Petersen, former Executive Director of Novartis's Natural Products Chemistry Department, and Professor Nadine Ziemert, one of Europe's foremost experts of microbial biosynthetic gene clusters.
Dr Vincent Libis, CSO and Co-Founder at Generare said: "Nature has been the n°1 source of innovative modes of action for drugs and we’ve only scratched the surface of its potential. We’re building the infrastructure to change that with the largest commercial library of evolution-derived molecules in the world, a dataset that improves with every cycle, and a platform that can supply companies with genuinely new starting points for drug discovery."
Maria Tahri, Bio Investor at Alven said: "While techbio is accelerating drug discovery, Generare is pushing it further, reopening nature’s pharmacy at industrial scale. By harnessing genomics, synthetic biology and machine learning, the company generates proprietary datasets on unknown mechanisms of action, unlocking drug opportunities others cannot see and building a moat that is already attracting strong industry interest.”
Paul Bazin, Partner at daphni said: "From penicillin onwards, modern pharma was born from natural products. Yet for decades the industry has been constrained by its inability to access new evolution-derived molecules. Generare removes this fundamental bottleneck. By unlocking the remaining 97% of natural products encoded in microbial genomes, they’re not just expanding chemical space, they’re redefining it. This marks a profound shift for the industry: the challenge is no longer designing new molecules, but understanding how to best translate this reservoir of biology into breakthroughs across healthcare and agriculture.”
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.